STAT July 5, 2024
Rachel Cohrs Zhang

WASHINGTON — A federal judge ruled against Boehringer Ingelheim’s challenge to the new Medicare drug price negotiation program, handing the pharmaceutical industry its latest in a string of legal losses.

The company had argued before the U.S. District Court of Connecticut that the drug pricing law was unconstitutional under four different parts of the Constitution,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Insurance, Medicare, Pharma, Pharma / Biotech
In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo
Pharma Pulse 10/3/24: Data Collection Complexities, 8 Things You May Not Know About Breast Cancer & more
New Techniques Make RNA Accessible to Study Variants of Uncertain Significance
Comprehensive strategies for prescription drug cost management
Gilead strikes deal to expand HIV drug access in 120 countries

Share This Article